Veraxa Biotech (NASDAQ:VRXA) Shares Cross Above Fifty Day Moving Average – Here’s Why

Veraxa Biotech Holding AG (NASDAQ:VRXA) passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $1.24 and traded as high as $1.3298. Veraxa Biotech shares last traded at $1.26, with a volume of 270,102 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Veraxa Biotech Stock Up 17.8%

The stock’s fifty day simple moving average is $1.24.

Insider Transactions at Veraxa Biotech

In related news, Director Oliver Baumann bought 50,000 shares of the stock in a transaction dated Thursday, August 27th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the director owned 5,773,618 shares in the company, valued at $8,660,427. This represents a 0.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christoph Samuel Ziegler bought 30,000 shares of the company’s stock in a transaction dated Tuesday, October 20th. The shares were acquired at an average cost of $1.09 per share, for a total transaction of $32,700.00. Following the completion of the transaction, the director owned 37,932 shares of the company’s stock, valued at approximately $41,345.88. The trade was a 378.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 95,000 shares of company stock worth $125,333.

About Veraxa Biotech

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.